Vestibular schwannomas (VS) are benign tumors with variable clinical behavior. Recurrence after surgery is uncommon yet sometimes aggressive. Reliable molecular predictors of recurrence are lacking, and the correlation between genotype and phenotype is weak. This study aimed to identify molecular markers associated with recurrence in VS and explore their prognostic potential.
✦ The floor
Discussion
Signed responses from readers of the wire.
Findings are preliminary biomarker-discovery research; no validated molecular test exists yet for clinical use, so no immediate change to surgical or monitoring protocols is warranted.
Identifying reliable molecular predictors of vestibular schwannoma recurrence could eventually guide post-surgical surveillance intensity and adjuvant therapy decisions.
- 01Transcriptomic and RT-qPCR analysis used to identify recurrence-associated gene expression patterns in vestibular schwannomas.
- 02Study targets a key clinical problem: predicting which tumors will regrow after surgical removal.
- 03Published in European Archives of Oto-Rhino-Laryngology (Aug 2026).
- 04Molecular biomarker discovery is an early step; clinical validation in prospective cohorts is still needed.
- 05Findings could inform future risk-stratified follow-up protocols for schwannoma patients.
Transcriptomic and RT-qPCR analysis can identify molecular predictors of vestibular schwannoma recurrence after surgery.
studypartially supported- PMID
- 42642532
- DOI
- 10.1007/s00405-026-10548-7.
- Journal
- European Archives of Oto-Rhino-Laryngology
- Publication type
- research_article
- Evidence level
- 4
- Population
- Patients with vestibular schwannomas who underwent surgical resection
- Intervention
- Transcriptomic profiling and RT-qPCR analysis of vestibular schwannoma tissue
Primary outcomes
Molecular predictors (gene expression signatures) associated with tumor recurrence after surgery